explore -WSS

explore

author：fashion 2025-09-02 22:00:24 - browse：9171

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Thermo Fisher plant for manufacturing gene therapies to expand

WSS

Medical student insurance fails on mental health care coverage

Medical student insurance fails on mental health care coverage

Lasker Awards 2023: Winners in biomedical research

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Ukraine and a new approach to mental health in war

explore

explore

knowledge

The high cost of giving birth even with insurance

UnitedHealth wins $3.3 billion takeover of Amedisys

Guidelines to prevent youth baseball injuries need more muscle

Lasker Awards 2023: Winners in biomedical research

Medical leaders decry Supreme Court decision on affirmative action

Illumina to lay off 10% of research and development team

Moonlake's readout produced a cash windfall. Risks remain

Ukraine and a new approach to mental health in war

How to save PrEP access — and even expand it

How Vertex's cystic fibrosis drug is changing patients' lives

hotspot

Second xenotransplant done with gene

Intarcia’s device

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

Lasker Awards 2023: Winners in biomedical research

Microbiome research is starting to find links to chronic diseases

GOP inquiry over gain

leisure time

Wikipedia

focus

hotspot